Mayne Pharma acquires generic Efudex
Mayne Pharma has acquired Spear Pharmaceutical's generic Efudex (fluorouracil cream 5%) for $20 million.
Generic Efudex is an antineoplastic topical cream indicated for the treatment of multiple actinic or solar keratoses, and for the treatment of superficial basal cell carcinomas when conventional methods of treatment are impractical.
Actinic Keratoses affects approximately 60 million Americans with the main cause being cumulative sun exposure.
Efudex cream 5% was originally approved by the FDA in 1970 and Spear is one of only two companies with a generic approval.
Generic Efudex had an annual market value of $66 million, according to IQVIA data.
“We are pleased to add generic Efudex to our product portfolio. Fluorouracil cream will further diversify earnings and strengthen Mayne Pharma’s position in the United States dermatology market,” Mayne Pharma’s CEO Scott Richards said. “Generic Efudex has a strong strategic fit with Mayne Pharma’s portfolio of generic and branded dermatology products and will be supported by our existing dermatology commercial capability across sales and marketing, customer service and medical affairs.”
Generic Efudex is an antineoplastic topical cream indicated for the treatment of multiple actinic or solar keratoses, and for the treatment of superficial basal cell carcinomas when conventional methods of treatment are impractical.
Actinic Keratoses affects approximately 60 million Americans with the main cause being cumulative sun exposure.
Efudex cream 5% was originally approved by the FDA in 1970 and Spear is one of only two companies with a generic approval.
Generic Efudex had an annual market value of $66 million, according to IQVIA data.
“We are pleased to add generic Efudex to our product portfolio. Fluorouracil cream will further diversify earnings and strengthen Mayne Pharma’s position in the United States dermatology market,” Mayne Pharma’s CEO Scott Richards said. “Generic Efudex has a strong strategic fit with Mayne Pharma’s portfolio of generic and branded dermatology products and will be supported by our existing dermatology commercial capability across sales and marketing, customer service and medical affairs.”